drugset / Trial / NCT05018975
Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.
Timeline
- Start
- 2022-01
- Primary completion
- 2023-09-21
- Completion
- 2023-09-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tazemetostat | Small molecule | 800 mg | Oral |